TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - H. LUNDBECK B Share Price

Certificat

DE000SQ2J9X4

Delayed Deutsche Boerse AG 08:04:22 02/07/2024 pm IST
1.75 EUR +4.79% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - H. LUNDBECK B
Current month-3.47%
1 month+3.73%
Date Price Change
02/24/02 1.75 +4.79%
01/24/01 1.67 -3.47%
28/24/28 1.73 +7.45%
27/24/27 1.61 +0.63%
26/24/26 1.6 -4.76%

Delayed Quote Deutsche Boerse AG

Last update July 02, 2024 at 08:04 pm IST

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying H. LUNDBECK A/S
IssuerLogo Issuer Société Générale Société Générale
WKN SQ2J9X
ISINDE000SQ2J9X4
Date issued 07/10/2022
Strike 26.19 kr
Maturity Unlimited
Parity 1 : 1
Emission price 0.07
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.08
Lowest since issue 0.055
Spread 0.01
Spread %0.57%

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
-
More about the company

Ratings for H. Lundbeck A/S

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: H. Lundbeck A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
38.6 DKK
Average target price
39.96 DKK
Spread / Average Target
+3.52%
Consensus